Four methods for the measurement of serum gentamicin concentration were evaluated with respect to cost-effectiveness, accuracy, and precision. Gentamicin concentration was determined in 112 clinical samples by the Staphylococcus epidermidis agar diffusion bioassay procedure in routine service in our laboratory at the time this study was initiated. Appropriate portions of these clinical samples were frozen and later thawed for remeasurement of gentamicin by bioassay or for measurement of gentamicin in one of three other systems. These included the Enzymatic Radiochemical Assay, the Diagnostic Products Corporation Radioimmunoassay and the New England Nuclear Corporation Radioimmunoassay. In addition, gentamicin dissolved in horse serum at 2, 4, 6, 8, 10, and 12 ,tg/ml was aliquoted, frozen, and later thawed for assay in each of the above systems. The data were analyzed for evidence of constant and proportional bias as well as for accuracy and precision.
Gentamicin is an aminoglycoside antibiotic used frequently in the treatment of gram-negative bacillary infections. It has a low therapeutic index and is potentially ototoxic and nephrotoxic. Serial monitoring of serum levels is an important factor in adjusting dosage of this antibiotic, especially if compromised renal function is present (3, 4, 7) . Our laboratory has used for several years a modification of the agar diffusion bioassay procedure (1, 6) to monitor serum gentamicin levels. This procedure is time-consuming, labor-intensive, and suffers from a lack of specificity (e.g., interference by other antimicrobial agents). More specific and rapid assays have been available for several years and include the enzymatic acetylating assay and the radioimmunoassay. Recently the enzymatic assay became commercially available as the Enzymatic Radiochemical Assay (ERA). The radioimmunoassay (RIA) is now available from a number of commercial sources. Previous comparative studies (5) indicate that each method has advantages and disadvantages which should be evaluated by individual laboratories to determine the method best suited to their needs. The purpose of the present study was to evaluate the ERA and two commercially available RIAs with a view to selecting the most appropriate method for measuring serum gentamicin levels of patients at our hospital.
MATERIALS AND METHODS Samples containing gentamicin. Two types of samples were used in this study. The first type consisted of 112 serum samples taken from patients receiving gentamicin. The concentration of gentamicin in each sample was determined initially upon receipt by the microbiology service by using the bioassay procedure described below. The remaining serum was stored frozen at 0°C in tightly capped plastic tubes.
Between 2 and 12 months later, the samples were thawed, and appropriate portions were refrozen at 0°C in tightly capped plastic tubes. Between 1 and 5 months after the portions were refrozen, they were thawed, and gentamicin concentration was remeasured in the bioassay or in the ERA, Diagnostic Products Corporation-RIA (DP-RIA), or New England Nuclear Corporation-RIA (NEN-RIA) as described below. The second type of sample assayed was made by dissolving gentamicin sulfate (Schering Corp., Kenilworth, N.J.; potency, 537 ,ug/mg) in sterile, filtered (0.45 ,um Nalgene filter; Nalgene Labware Div., Nalge/ Sybron Corp., Rochester, N.Y.) horse serum (HS; Microbiological Associates, Walkersville, Md.). Gentamicin was dissolved in HS to a concentration of 24 ,ug/m.l. Appropriate dilutions of this solution were made by using HS to obtain solutions containing gentamicin at concentrations of 2, 4, 6, 8, 10, and 12 ,ug/ ml, respectively. Amounts of these solutions were frozen (0°C) in tightly capped plastic tubes and thawed between 1 and 5 months later for measurement of gentamicin concentration in each of the four assay systems.
With minor modifications, the assay performed in our laboratory was similar to that (1, 6) 10, and 20 yig/ml were prepared from the kit. A working reagent for each assay was prepared from the kit being used and contained 10 volumes of buffer solution, 1 volume of ['4C ]acetyl coenzyme A, and 1 volume of gentamicin acetyltransferase. Sixty ,ul of this working solution was pipetted into each polypropylene tube (12 by 75 mm). All samples were assayed in duplicate. At timed intervals of 30 s, 10 pl of sample was added to the appropriate assay tube, the contents were mixed, and the tube was placed in a 37°C water bath.
Exactly 10 min later in timed sequence, 50 jul of each reaction mixture was pipetted onto a numbered phosphocellulose paper disk previously mounted on a stainless steel pin stuck in a polystyrene mounting board. After allowing at least 1 min for the reaction product to adsorb to the paper, all disks and pins were removed from the mounting board and dropped into a beaker containing a minimum of 10 ml of distilled water for each sample disk to be washed. The contents of the beaker were swirled gently for 2 min, the distilled water was decanted, and the beaker was refilled with the same volume of distilled water. The contents of the beaker were swirled and allowed to stand at least 2 min. A third wash was performed in the same manner. The pin and paper disks were transferred to an absorbent paper towel. Pins were removed, and disks were arranged in numerical order. Each disk was blotted gently and placed in an appropriately numbered scintillation vial. To each vial was added 0.5 ml of ammonium hydroxide (1.4 mol/liter), thoroughly wetting the paper disk. After allowing at least 1 min to elapse, 12 ml of scintillation cocktail (Packard InstaGel; Packard Instrument Co., Downers Grove, Ill.) was added to each vial, the contents were swirled, and the vials were counted for 1 Duration of the study. The duration of this study was 7 months. During month 1, 8% of the ERA experiments were performed. During month 2, the percentages of assays performed were: ERA, 42%; bioassay, 33%; DP-RIA, 15%; and NEN-RIA, 0%. In month 3, the percentages were: ERA, 33%; bioassay, 33%; DP-RIA, 15%; and NEN-RIA, 0%. In month 4, the percentages were: EPA, 17%; bioassay, 26%; DP-RIA, 0%; and NEN-RIA, 0%. In month 5, 8% of the bioassay experiments were performed. In month 6, 35% of the DP-RIA and 50% of the NEN-RIA experiments were performed. In month 7, the percentages were the same as for month 6. No consistent significant changes in the mean values for the HS gentamicin samples were noted over this 7-month period with any of the assay methods. Figure 1 shows a standard curve for the bioassay based on 12 separate experiments. The xaxis shows the gentamicin concentration in micrograms per milliliter, whereas the y-axis shows the size in millimeters of the diameter of the zone of growth inhibition. The data are expressed as the mean plus or minus one standard deviation. Figure 2 for the DP-RIA is shown in Fig. 3 Figure 4 shows the standard curve for the NEN-RIA with the natural logarithm of the gentamicin concentration on the x-axis and the percent maximum binding of ['25I ]gentamicin on the y-axis. The mean plus or minus one standard deviation of 20 experiments is shown.
RESULTS
In Fig. 5 respectively. The nominal values of these materials were reported as 3.0 and 12.0 ,tg/ml. Thus, the method appears to have been in control by the criteria of the quality control material included with the kit. Since the 95% confidence interval excluded the value 1.0 for the slope in the bioassay, the bioassay appears to exhibit proportional bias. Table 2 presents precision data for each method. The results are expressed as coefficients of variation at each concentration for which gentamicin was measured. There was no outstanding difference in the range of coefficient of variation values for the different assay systems. The data in Fig. 6 show the results of a linear regression analysis in which the results for clinical samples measured in the ERA (y-axis) are compared to the results in the repeat bioassay (x-axis). The results for clinical samples mea- would make the utilization of 500-tube assay kits reasonable. Table 6 shows the cost of determininm the DP-RIA (y-axis) are plotted in Fig.. .*..
Linst the values obtained in the repeat bioas-mig a single serum gentamicin concentration as (x-axis). Likewise, Fig. 8 shows the NEN-a function of the method used and as a function values for the clinical samples compared of the size kit from which materials are obtained, the values obtained in the repeat bioassay.
as well as the cost of obtaining a single gentable 5 summarizes some of the important micin level when it is run in a batch of six levels. ts of the regression analyses in Fig. 6, 7 , and The data are given in terms of method used as 1M n^rl;">fx> "g! il n 7A A Qil r., well as size of kit used. o. i ne correiuaion coeiiicients are u. i4, u.Ou, ana 0.81 for the ERA, DP-RIA, and NEN-RIA, respectively. The column labeled P in Table 5 suggests that none of the methods appeared to have y-intercepts significantly different from 0 (e.g., none of the methods appeared to show significant evidence of constant bias). However, for each of the methods, the 95% confidence interval excluded the value of 1.0 bias in the ERA, DP-RIA, or NEN-RIA, when compared to the bioassay reference method. However, each of these methods shows proportional bias, compared to the repeat bioassay. The data on recovery argued against two methods: the bioassay appeared to underestimate, whereas the NEN-RIA appeared to overestimate, gentamicin concentration to some extent. Two of the methods, the ERA and DP-RIA, appeared very similar with respect to accuracy (the percent recoveries were very close to 100%). Cost analysis of these methods argued in favor of one of the commercial methods. Another consideration may be the existing equipment in a laboratory, such as scintillation or gamma counters.
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